Sign up Australia
Proactive Investors - Run By Investors For Investors

Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials

Placement anchored by A$10 million from UK fund Lanstead Capital.
Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials
Rett syndrome program granted ‘Fast Track’ designation by FDA

Neuren Pharmaceuticals (ASX:NEU) has secured a funding of A$11.5 million via the placement of shares at $0.062 each, to enable the initiation of key activities for commencing a Phase 3 trial in Rett syndrome.

Neuren is focused on developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders.

The company presently has a clinical stage molecule, trofinetide in Phase 2 clinical trials.

Trofinetide is being developed both in intravenous and oral formulations for a range of acute and chronic conditions.

The most advanced program is for Rett syndrome, supported by rettsyndrome.org.

The Rett syndrome program has been granted fast track designation by the U.S. FDA and have an orphan drug designation in both the U.S. and the European Union.

Neuren’s placement raising A$11.5 million is anchored by A$10 million from the UK fund Lanstead Capital, with supporting investments from Rettsyndrome.org and Neuren’s directors and management.

Neuren plans to meet with the US FDA Division of Neurology in the third quarter of 2017 to discuss the remaining development for trofinetide to treat Rett syndrome, including the Phase 3 trial design.

In parallel with the FDA interactions, Neuren can now initiate the following key manufacturing and nonclinical activities that are required to be completed before a Phase 3 trial can commence:

- conclude optimisation of the drug substance manufacturing process for commercial supply;
- conclude stability testing and analytical validation of the new to-be-marketed liquid drug formulation; and
- conduct non-clinical toxicity study in a second species, which is required for a Phase 3 trial with longer dosing.

The cash flow for these activities will occur in the second half of 2017 and the first half of 2018.

View full NEU profile View Profile

Neuren Pharmaceuticals Ltd Timeline

Related Articles

cancer cell
February 01 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
cancer
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use